{"id":"W2797309423","doi":"10.1056/nejmoa1802357","title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1853,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; EUSA Pharma; Merck Sharp and Dohme; Eisai; Universiteit van Amsterdam; Incyte; LEO Pharma; Massachusetts Medical Society; Sun Pharma; Regeneron Pharmaceuticals; Syndax Pharmaceuticals; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Adjuvant; Placebo; Stage (stratigraphy); Medicine; Melanoma; Oncology; Internal medicine; Cancer research; Cancer; Biology; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03049556086374712,"score_gpt":0.3167479901321354,"score_spread":0.2862524292683883,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}